COMPANY:

SAGA Diagnostics

"SAGA Diagnostics...joins collaborators from the Karolinska Institutet to present new clinical data showcasing the ultrasensitive detection of ctDNA in colorectal cancer (CRC) using Pathlight at the 2026 American Society for Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, January 8-10 in San Francisco, CA."

"SAGA Diagnostics®...joined collaborating investigators at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, TX this week to present data from two trials evaluating neoadjuvant therapy outcomes in triple-negative breast cancer (TNBC)."

"SAGA Diagnostics...redefining the standard for ultra-sensitive and early molecular residual disease (MRD) detection, will present five posters—three new studies and two trials in progress—at the 2025 San Antonio Breast Cancer Symposium (SABCS), December 9-12, 2025 in San Antonio, TX."

"SAGA Diagnostics AB...has entered into an assay development agreement with the global, science-led biopharmaceutical company AstraZeneca...SAGA Diagnostics will in the course of this agreement develop unique SAGAsafe® dPCR assays towards undisclosed methylated targets for analyses of tissue samples and liquid biopsies."

"SAGA Diagnostics AB...adapted a SAGAsafe® PIK3CA 24-plex mutation detection assay to work on Stilla Technologies’ new naica® Prism 6 system which was presented at this year’s Annual Meeting of the American Society of Human Genetics (ASHG) on October 14."